HARMONI-GI1, A PHASE III TRIAL FEATURING IVONESCIMAB PLUS CHEMOTHERAPY COMPARED TO DURVALUMAB PLUS CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED BILIARY TRACT CANCER FROM CHINA, TO BE SHOWCASED IN PRESIDENTIAL SYMPOSIUM AT ESMO 2026

Reuters · 1d ago

Please log in to view news